Want to see LXRX full AI Analyst Report?
LXRX Stock Chart & Stats
$2.29
>-$0.01(-0.43%)
At close: 4:00 PM EDT
$2.29
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$1.01 - $2.68
Previous CloseN/A
Volume1.68M
Average Volume (3M)4.03M
Market Cap
$1.03B
Enterprise Value$511.43
Total Cash (Recent Filing)$170.66M
Total Debt (Recent Filing)$57.71M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Aug 06, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding444,196,380
10 Day Avg. Volume2,625,675
30 Day Avg. Volume4,028,280
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.88
Price to Sales (P/S)8.38
P/FCF Ratio-6.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.03Price Target Upside119.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$38.17M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & High Gross MarginsMaterial revenue step‑up together with near‑100% gross margins indicates Lexicon’s ability to monetize assets via high‑margin milestone and royalty streams. Over months this improves headline revenue quality when milestones hit, enhances gross profit contribution and supports funding for R&D without full commercial scale.
Stronger Liquidity & Capital FlexibilityNearly $200M in cash plus an initial draw on a $100M term loan materially extends Lexicon’s runway, lowers near‑term refinancing pressure and funds ongoing trials. The facility’s interest‑only period and repayment of prior debt improve short‑term liquidity and give management time to reach clinical inflection points.
Late‑stage Clinical MomentumCompletion of randomization in the pivotal SONATA‑HCM trial and progress across other programs (LX9851 Phase I, pilavapadin Phase III readiness) reduces execution uncertainty. Enrollment completion shifts risk from recruitment to readout, creating a clearer path to topline data, regulatory actions and partner/commercial decisions over the coming months.
Bears Say
Persistent Negative Cash FlowDespite improvement from prior years, roughly -$39M TTM operating and free cash flow shows Lexicon still consumes cash. Over a 2–6 month horizon this necessitates continued reliance on milestone receipts or external financing, keeping dilution and liquidity risk elevated if clinical or partner payments are delayed.
Milestone‑driven, Concentrated RevenueThe recent revenue spike was largely two partner milestones, with minimal organic product sales. This concentration makes topline results lumpy and dependent on third‑party timing and execution, limiting predictable cash generation and increasing vulnerability if partners delay or fail to achieve triggers.
Conditional Financing Tranches & CovenantsAccess to the full $100M facility depends on clinical/regulatory milestones and lender consent; the loan includes covenants and warrants. If milestones slip, subsequent tranche availability and covenant headroom could tighten, constraining strategic flexibility and increasing the chance of dilutive or restrictive financing alternatives.
Lexicon Pharmaceuticals News
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $1.01 and its highest was $2.68 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $1.03B.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 5 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on May 07, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.034 by $0.034.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.05.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 444,196,380 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of $0 in its last earnings report, beating expectations of -$0.034. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexicon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.03 (119.80% Upside)
$5.03 (119.80% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 41.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.69%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
LXRX Company Deck
LXRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial progress across multiple fronts: large milestone-driven revenue, meaningful improvements in net loss, a stronger liquidity position, and clear clinical development milestones (SONATA enrollment completion mid-2026; Zynquista NDA resubmission midyear; LX9851 in Phase I; pilavapadin Phase III readiness). At the same time, several risks remain: the revenue uplift was largely one-time milestone-driven with limited organic sales, continued dependence on partners and conditional debt tranches, regulatory and enrollment uncertainties, and competitive dynamics in HCM. On balance, the highlights — particularly financial strengthening and late-stage program momentum — outweigh the lowlights, though execution risk into the second half of 2026 remains important.View all LXRX earnings summariesLXRX Stock 12 Month Forecast
Average Price Target
$5.03
▲(119.80% Upside)
Technical Analysis
Ownership Overview
61.35% Insiders
7.89% Mutual Funds
0.15% Other Institutional Investors
24.69% Public Companies and
Individual Investors